Eyecuracy, Ltd. (Israel)
The Multisensory Research Group at the University of Regensburg, headed by Prof. Mark W. Greenlee and Prof. Anton L. Beer, has been collaborating with Eyecuracy, Ltd. (Israel) on the validation and refinement of Eyecuracy's calibration-less, AI-powered eye-tracking platform.
The Multisensory Research Group at the University of Regensburg, headed by Prof. Mark W. Greenlee and Prof. Anton L. Beer, has been collaborating with Eyecuracy, Ltd. (external link, opens in a new window) (Israel) on the validation and refinement of Eyecuracy's calibration-less, AI-powered eye-tracking platform. Eyecuracy combines lightweight, user-friendly eye-tracking glasses with a cloud-based service running proprietary AI algorithms, enabling the detection of digital oculomotor biomarkers without the tedious per-user calibrations that limit clinical adoption of conventional gaze trackers.
The collaboration draws on the complementary strengths of the two partners. Eyecuracy contributes the hardware, software framework, and AI engine — protected by four patent families across the USA, Europe, China, Japan, and Taiwan, with eight patents granted in 2025–2026. The Multisensory Research Group contributes deep expertise in human visual and oculomotor neuroscience, multisensory integration of visual, vestibular, and proprioceptive signals, and a research infrastructure suited to clinically relevant cohorts through close ties with the University of Regensburg Eye Clinic.
To date, the partnership has delivered one of the five successful pilot studies that anchor Eyecuracy's clinical evidence base, alongside parallel work at the UC Berkeley School of Optometry. The Regensburg arm has focused on initial assessment of the system's accuracy in detecting eye-movement biomarkers relevant to Binocular Vision Disorders (BVD) — Eyecuracy's fastest path to market — and on the feasibility of extending the platform to broader neurological conditions, including mild traumatic brain injury (concussion), multiple sclerosis, and Parkinson's disease.
Going forward, the partners plan to scale the pilot work into larger validation studies, refine biomarker definitions for clinical use, and explore in-home monitoring scenarios consistent with Eyecuracy's hybrid in-clinic plus telehealth deployment model — supporting Eyecuracy's mission to bring objective, scalable neuro-ophthalmic diagnostics to underserved patient populations.
Further Reading:
Greenlee, M.W., Keil, E. Plank, T., Jaegle, H., Chen, D.M.L., Lu, I., Vorobey, A., Shovman, M., Kashchenevsky, A. (2026) Accurate AI-assisted binocular limbus eye tracking in participants performing visually guided eye-movement tasks. Under review. https://github.com/mark-shovman/Greenlee_etal_2026_data (external link, opens in a new window)